Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 known ✓ | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5555716 | 1.00 | ANPEP (0.44) | ANPEPTDP1MEN1KMT2ANOS3 | |
| SCHEMBL8246840 | 0.88 | — | — | |
| SCHEMBL5160397 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL2439875 | 0.86 | ANPEP (0.47) | ANPEPTDP1MEN1KMT2ANOS3 | |
| Hydrochloric Acid SCHEMBL16114150 | 0.86 | ANPEP (0.47) | ANPEPTDP1MEN1KMT2ANOS3 | |
| Acetic Acid SCHEMBL3421514 | 0.80 | ANPEP (0.47) | ANPEPTDP1MEN1KMT2APAOX | |
| Hydrochloric Acid SCHEMBL7055449 | 0.78 | UBE2N (0.48) | ANPEPTDP1MEN1KMT2APAOX | |
| Acetic Acid SCHEMBL3180181 | 0.78 | ANPEP (0.44) | ANPEPTDP1MEN1KMT2APAOX | |
| Acetic Acid SCHEMBL28384916 | 0.78 | ANPEP (0.44) | ANPEPTDP1MEN1KMT2APAOX | |
| Acetic Acid SCHEMBL3657736 | 0.76 | CA12 (0.59) | TDP1MEN1KMT2APAOXCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7175829-B2 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies | EPIX PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20050118103-A1 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2005-06-02 | — | — | US | disclosed |
| US-6861045-B1 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies | LANTHEUS MEDICAL IMAGING, INC. | 2005-03-01 | — | — | US | disclosed |
| EP-1019094-B1 | CONTRAST-ENHANCED DIAGNOSTIC IMAGING METHOD FOR MONITORING INTERVENTIONAL THERAPIES | EPIX MEDICAL INC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1021452-B1 | PROCESS FOR SYNTHESIZING PHOSPHODIESTERS | EPIX MEDICAL INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1019094-A2 | CONTRAST-ENHANCED DIAGNOSTIC IMAGING METHOD FOR MONITORING INTERVENTIONAL THERAPIES | Epix Medical, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5919967-A | Process for synthesizing phosphodiesters | EPIX MEDICAL, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1999017809-A2 | CONTRAST-ENHANCED DIAGNOSTIC IMAGING METHOD FOR MONITORING INTERVENTIONAL THERAPIES | EPIX MEDICAL, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050118103-A1 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies | FABP3, FABP1, SDCBP | NOS3 4219/4885NOS1 4529/4885ANPEP 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.